Catalyst Pharmaceuticals, Inc.
CPRX
Rank in Stocks
#4167
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Share Price
$31.49
Last synced: 2026-07-21
Market Cap
$3.85B
Change (1 day)
0.00%
Change (1 year)
53.24%
Country
US
Trade Catalyst Pharmaceuticals, Inc. (CPRX)
Category
Healthcare
Operating Margin for Catalyst Pharmaceuticals, Inc. (CPRX)
Operating Margin as of October 2026 TTM: 44.83%
According to Catalyst Pharmaceuticals, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 44.83%. At the end of 2023 the company had an Operating Margin of 21.80%.
Operating Margin history for Catalyst Pharmaceuticals, Inc. from 2002 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 44.83% | 12.98% |
| 2024 | 39.68% | 82.02% |
| 2023 | 21.80% | -54.14% |
| 2022 | 47.54% | 27.80% |
| 2021 | 37.20% | 7.24% |
| 2020 | 34.69% | 11.51% |
| 2019 | 31.11% | -100.44% |
| 2018 | -7,059.03% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | -100.00% |
| 2010 | -823.01% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.14% |
US
|
|
| -149.01% | -103.32% |
US
|
|
| 25.57% | -99.43% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.36% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.